Počet záznamov: 1
sorafenib
SYS d000077157 LBL 00000nx^^^2200181-^^45^^ 005 20240119195325.3 100 $a 20190101asloy0103 ba0 152 $b mesh 250 $a sorafenib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $8 slo 300 1-
$a 2019 (2003) $8 eng 330 1-
$a A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. $8 eng 450 $a Nexavar $5 e $8 slo 450 $a sorafenib N-oxid $5 e $8 slo 450 $a sorafenib tozylát $5 e $8 slo 686 $a D02.065.950.681.757 686 $a D02.455.426.559.389.703.757 686 $a D03.066.515.530.750 686 $a D03.383.725.547.530.750 750 $a Sorafenib $8 eng 801 -0
$a SK $b BA006 $c 20190310 801 -2
$a SK $b BA006 $c 20190708 980 $x M
Počet záznamov: 1